RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  2. Study siteShanghai Sixth People's Hospital上海市第六人民医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07538973, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Child-Pugh Class A or B;

    Inclusion criterion 10

  3. No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.

    Inclusion criterion 12

    Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening;

    Exclusion criterion 11

  4. Creatinine clearance (CLcr) < 60 mL/min (calculated by the Cockcroft-Gault formula);

    Exclusion criterion 15

  5. Tested positive for HIV or syphilis screening;

    Exclusion criterion 4

    Used any CYP3A4 inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening;

    Exclusion criterion 7

    Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening;

    Exclusion criterion 21

  6. Subjects and their partners agree to voluntarily adopt effective contraceptive measures from screening until 6 months after the last dose;

    Inclusion criterion 4

    Female subjects who are lactating or test positive for pregnancy during screening or the trial period;

    Exclusion criterion 16

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07538973, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

All subjects must meet all of the following inclusion criteria:

  • Provide signed informed consent prior to trial participation and have a full understanding of the trial content, procedures, and potential adverse reactions;
  • Be male or female subjects aged 18 to 65 years (inclusive);
  • Weigh at least 50 kg for males and at least 45 kg for females. Body Mass Index (BMI = weight (kg) / height² (m²)) within the range of 18 to 30 kg/m² (inclusive of boundary values);
  • Subjects and their partners agree to voluntarily adopt effective contraceptive measures from screening until 6 months after the last dose;
  • Subjects are able to communicate well with the investigators and can complete the study according to the study protocol.

Subjects with normal liver function must also meet the following inclusion criteria:

  • Negative test results for Hepatitis B surface antigen and Hepatitis C antibody;
  • Normal liver function test results or abnormal results without clinical significance;
  • Matched with the hepatic impairment group in terms of male-to-female ratio (±1 subject per gender), mean age (±10 years), and mean body weight (±10 kg).

Subjects with hepatic impairment must meet the following inclusion criteria:

  • Have a history of or be diagnosed at screening with primary liver disease, including but not limited to: Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, etc.;
  • Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Child-Pugh Class A or B;
  • Liver function is stable within 2 weeks prior to taking the study drug, as determined by the investigator;
  • No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.

Exclusion Criteria:

All subjects who meet any of the following exclusion criteria are not eligible for enrollment:

  • Suffering from primary diseases of major organs, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, oncological, immune, psychiatric, or cardiovascular diseases, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);
  • Physical examination, vital signs, or clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function) show abnormalities of clinical significance, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);
  • Participated in any drug clinical trial and used any investigational drug within 3 months prior to screening;
  • Tested positive for HIV or syphilis screening;
  • Subjects with conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug (e.g., inability to swallow) or who have undergone gastrointestinal resection that may affect drug absorption, distribution, metabolism, or excretion;
  • Electrocardiogram (ECG) abnormalities of clinical significance (e.g., tachycardia/bradycardia requiring medication, second- or third-degree atrioventricular block, or other abnormalities deemed clinically significant and unsuitable for participation by the Investigator);
  • Used any CYP3A4 inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening;
  • Used any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements (e.g., vitamins, calcium supplements) within 2 weeks prior to screening, except for medications used by hepatic impairment patients to treat hepatic impairment and its complications;
  • Known allergy to any component of TQ-B3101 capsules, or having an allergic constitution (including a history of drug allergy, prone to rashes, eczema, urticaria, asthma, etc.);
  • Smoked an average of more than 5 cigarettes per day within 3 months prior to screening;
  • Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening;
  • Alcoholic liver disease patients have a history of alcoholism within 12 months prior to screening; other subjects have a history of alcoholism within 3 months prior to screening (average daily alcohol consumption > 2 units [1 unit = 360 mL beer or 45 mL 40% spirits or 150 mL wine]);
  • Donated blood or plasma, lost ≥ 200 mL of blood, or undergone plasmapheresis within 4 weeks prior to screening;
  • Consumed any food or beverage containing alcohol (or tested positive for alcohol breath test 1 day before dosing; alcoholic liver disease subjects consumed any alcohol-containing substances 2 weeks before dosing), grapefruit juice/pomelo juice, coffee, tea, cola, or chocolate within 1 week before dosing;
  • Creatinine clearance (CLcr) < 60 mL/min (calculated by the Cockcroft-Gault formula);
  • Female subjects who are lactating or test positive for pregnancy during screening or the trial period;
  • Deemed by the Investigator to have any factors making them unsuitable for participation in this trial.

Subjects with hepatic impairment must also meet the following additional exclusion criteria:

  • History of liver transplantation;
  • Experienced hepatic encephalopathy within 30 days prior to screening;
  • Used any medication that may cause acute hepatotoxicity (e.g., halothane and methotrexate) within 3 months prior to screening;
  • Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening;
  • Experienced a rapid deterioration or Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) elevation > 3 times the upper limit of normal within 2 weeks prior to dosing, as judged by the Investigator;
  • Experienced worsening of hepatic encephalopathy within 30 days prior to dosing;
  • Suffering from diseases affecting bile excretion, such as biliary cirrhosis, hepatic/biliary obstruction, or cholestatic liver disease;
  • Patients with liver failure or complications deemed unsuitable by the Investigator, such as hepatic encephalopathy, hepatocellular carcinoma, esophageal-gastric variceal bleeding within 3 months, severe portal hypertension, or history of portosystemic shunt surgery;
  • As judged by the Investigator, having concomitant medications that may potentially affect the evaluation of the pharmacokinetic characteristics of TQ-B3101 and its metabolites.

Quoted from ClinicalTrials.gov, NCT07538973, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07538973, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07538973